Stocktoria
Kura Oncology, Inc. KURA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-05
Kura Oncology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -449.9% | -358.5% | — | — | — |
| Net margin | -412.9% | -322.9% | — | — | — |
| FCF margin | -104.8% | 248.4% | — | — | — |
| Return on assets | -37.7% | -22.9% | -34.0% | -29.8% | -24.4% |
| Return on equity | -160.0% | -42.1% | -38.4% | -32.3% | -25.8% |
| Debt / equity | 0.06× | 0.02× | 0.02× | 0.02× | — |
| Current ratio | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 |
| Revenue growth | 25.2% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001422143 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.